Children's Tumor Foundation President Annette Bakker wrote an oped for BioProcess International about the BRIDGE Initiative, a partnership with CureSearch for Children’s Cancer and FasterCures, a division of the Milken Institute, which is a neutral information and matchmaking forum for connecting shelved drug assets (SDAs) with partners that have the expertise and capital needed to develop those medicines.
The Bridge team believes that all relevant SDAs for pediatric and/or rare diseases should be repositioned for pediatric and/or rare diseases. Despite efforts from governments around the world — and incentives such as the Orphan Drug Act and the rare pediatric voucher program from the US Food and Drug Administration (FDA) — rare diseases and pediatric cancers continue to suffer from a lack of industry attention.
Click here to read the article.
